Dr. Cheah on the efficacy of TG-1701 alone and in combination with U2 in CLL


Chan Cheah, MBBS, discusses the results of a study evaluating the efficacy and safety of TG-1701 alone and in combination with ublituximab and umbralisib in chronic lymphocytic leukemia.

Chan Cheah, MBBS, Clinical Professor, University of Western Australia (WA), Consultant Hematologist, Lymphoma Manager, Fellowship Program Director, Sir Charles Gairdner Hospital, Pathwest Laboratory Medicine WA, Linear Clinical Research and Hollywood Private Hospital, Founder, Blood Cancer Research WA, discusses the results of a study evaluating the efficacy and safety of TG-1701 alone and in combination with ublituximab (TG-1101) and umbralisib (Ukoniq; U2) in chronic lymphoid leukemia (LLC).

During the International LLC Workshop 2021, the results of an ongoing phase 1 trial (NCT03671590) evaluating TG-1701, a selective BTK inhibitor, as monotherapy and in combination with U2 in patients with CLL were presented virtually. Single agent TG-1701 demonstrated an objective response rate (ORR) of 83%. Additionally, all 3 patients who received the triplet diet achieved an objective response, explains Cheah.

By disease-specific cohort, the ORR was 95% in patients who received 200 mg of TG-1701 and 100% in patients who received 300 mg of TG-1701 at a median follow-up of 19 months and 12 months , respectively. Ultimately, these results indicate that TG-1701 is an effective inhibitor of BTK alone or in combination with U2 in CLL, concludes Cheah.

About Hector Hedgepeth

Check Also

Oxford BioDynamics Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) Now Available in the UK

Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for …

Leave a Reply

Your email address will not be published.